These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7504213)

  • 1. Induction of fetal hemoglobin by recombinant human erythropoietin in patients with end-stage renal disease.
    Salvati F
    Nephron; 1993; 65(2):313. PubMed ID: 7504213
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect on hemoglobin F synthesis by erythropoietin in patients with anemia of end-stage renal disease maintained by chronic hemodialysis.
    Salvati F; Strippoli P; Barchetti M; Scatizzi A
    Nephron; 1992; 60(3):371. PubMed ID: 1373475
    [No Abstract]   [Full Text] [Related]  

  • 3. [Recombinant human erythropoietin stimulates synthesis of fetal hemoglobin in patients with renal anemia treated by repeated hemodialysis].
    Hanicki Z; Sułowicz W; Stepniewski M; Kuźniewski M; Kraśniak A; Kopeć J; Cieszkowska U; Solarska K
    Pol Arch Med Wewn; 1991 Jun; 85(6):352-5. PubMed ID: 1716757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human erythropoietin stimulates synthesis of fetal haemoglobin in haemodialysed patients with anaemia due to end-stage kidney.
    Hanicki Z; Sułowicz W; Stepniewski M; Kuźniewski M; Kraśniak A; Kopeć J; Cieszkowska U; Stolarska K
    Contrib Nephrol; 1990; 87():11-4. PubMed ID: 1709603
    [No Abstract]   [Full Text] [Related]  

  • 5. Hemoglobin F levels in end-stage renal disease patients after correction of anemia with erythropoietin.
    Sikole A; Efremov DG; Dimovski A; Efremov GD; Polenakovic M
    Nephron; 1993; 65(3):482-4. PubMed ID: 7507224
    [No Abstract]   [Full Text] [Related]  

  • 6. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
    Frenken LA; Verberckmoes R; Michielsen P; Koene RA
    Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels.
    Kooistra MP; Struyvenberg A; van Es A
    Nephron; 1991; 57(1):127-8. PubMed ID: 2046808
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of recombinant human erythropoietin and darbepoetin alpha in children.
    Can C; Emre S; Bilge I; Yilmaz A; Şirin A
    Pediatr Int; 2013 Jun; 55(3):296-9. PubMed ID: 23461764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candidate biomarkers for erythropoietin response in end-stage renal disease.
    Besarab A; Yee J
    Kidney Int; 2011 Mar; 79(5):488-90. PubMed ID: 21321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Two new drugs. Recombinant "human" erythropoietin (EPO: Erypo, Recormon)].
    Verwiebe R
    Internist (Berl); 1992 Apr; 33(4):279-81. PubMed ID: 1612854
    [No Abstract]   [Full Text] [Related]  

  • 12. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
    Nikolaev AIu; Klepikov PV; Lashutin SV
    Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
    [No Abstract]   [Full Text] [Related]  

  • 13. Recombinant human erythropoietin therapy in end stage renal failure.
    Watson AJ; Spivak JL
    J Clin Pharmacol; 1988 Dec; 28(12):1086-8. PubMed ID: 3072351
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunological effects of recombinant human erythropoietin on end-stage renal disease pediatric and adult patients.
    Salvati F; Liani M; La Torre M; Golato M; Di Sciascio N; Pietrzyk J; Dyras P
    Nephron; 1994; 68(4):510-1. PubMed ID: 7870240
    [No Abstract]   [Full Text] [Related]  

  • 15. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin.
    N Engl J Med; 1987 Jul; 317(4):249-51. PubMed ID: 3600716
    [No Abstract]   [Full Text] [Related]  

  • 16. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 17. Recombinant human erythropoietin: duplicate publication.
    Warady BA
    Pediatr Nephrol; 1991 Nov; 5(6):763. PubMed ID: 1768593
    [No Abstract]   [Full Text] [Related]  

  • 18. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
    N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. The Canadian Erythropoietin Study Group.
    Keown PA
    Contrib Nephrol; 1991; 88():81-6; discussion 87-9. PubMed ID: 2040199
    [No Abstract]   [Full Text] [Related]  

  • 20. Resistance to recombinant human erythropoietin in a hemodialysis patient with lupus reactivation.
    Romero R; Novoa D; Perez-Freiria A; Arcocha V; Alonso R; Arza D; Lens XM; Sanchez-Guisande D
    Nephron; 1995; 69(3):343-4. PubMed ID: 7753275
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.